2021
Triple-negative breast cancer: promising prognostic biomarkers currently in development
Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Review Of Anticancer Therapy 2021, 21: 135-148. PMID: 33198517, PMCID: PMC8174647, DOI: 10.1080/14737140.2021.1840984.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerHuman epidermal growth factor receptor 2Vascular endothelial growth factorHomologous recombination deficiencyBreast cancerEpidermal growth factor receptorGrowth factor receptorPredictive biomarkersTreatment optionsFibroblast growth factor receptorManagement of TNBCEpidermal growth factor receptor 2Factor receptorGrowth factor receptor 2PI3K/Akt/mTORLimited treatment optionsNTRK gene fusionsFactor receptor 2Akt/mTOREndothelial growth factorCell-free DNAAntibody-drug conjugatesClinical outcomesImmune biomarkersPoor prognosis
2012
Multiparameter Analysis, including EMT Markers, on Negatively Enriched Blood Samples from Patients with Squamous Cell Carcinoma of the Head and Neck
Balasubramanian P, Lang J, Jatana K, Miller B, Ozer E, Old M, Schuller D, Agrawal A, Teknos T, Summers T, Lustberg M, Zborowski M, Chalmers J. Multiparameter Analysis, including EMT Markers, on Negatively Enriched Blood Samples from Patients with Squamous Cell Carcinoma of the Head and Neck. PLOS ONE 2012, 7: e42048. PMID: 22844540, PMCID: PMC3406036, DOI: 10.1371/journal.pone.0042048.Peer-Reviewed Original ResearchConceptsEpithelial surface markersN-cadherinEpidermal growth factor receptorGrowth factor receptorSurface markersPositive selection approachEpithelial markersAforementioned proteinsMesenchymal transitionFactor receptorConfocal microscopyCancer metastasisEMT processCancer cellsPhenotypic patternsMesenchymal markersTumor metastasisEnrichment methodologyEMT markersEnrichment technologyCellsEMTExpressionTumor cellsMarkers